Reprinted with permission from InsideCounsel.
A March decision from the Indian Patent Office has caught the attention of pharmaceutical patent holders around the world. For the first time in India, a generic drug manufacturer has been granted a compulsory license to manufacture and sell a generic version of a patented drug. Though Bayer Corp., the drug's manufacturer, has appealed, the decision may provide a framework that supports future efforts at compulsory licensing in India and, perhaps, beyond.
Read the full article by clicking the link below.
IP: India's Compulsory Licensing Case
The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.